LARIMAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.53 USD | +2.35% |
|
-6.18% | +43.52% |
| Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
| Mar. 14 | Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Larimar Therapeutics, Inc.
4b541625a.CGIlgchS8pOcdQeA69XRLke2UBpzw1tLFeXbNOxnUGw.fxhP44pnlenQFD-2gJC6awb8H240gi4vX4yiULkEZAM4T2zRmyuzvuQ7Nw~946145c5adc80870f4365e2fd2e263d4
Upcoming events on Larimar Therapeutics, Inc.
Past events on Larimar Therapeutics, Inc.
| 2024-03-14 04:05 pm | Q4 2023 Earnings Release |
| 2024-03-13 10:00 am | Leerink Partners Global Biopharma Conference |
| 2024-02-12 08:00 am | Nomlabofusp Phase IIb Top line Data Results Call |
| 2023-11-14 07:00 am | Q3 2023 Earnings Release |
| 2023-11-07 01:10 pm | Guggenheim Securities Inflammation & Immunology Conference |
| 2023-09-06 08:50 am | Citi BioPharma Conference |
| 2023-08-10 07:00 am | Q2 2023 Earnings Release |
| 2023-07-25 08:00 am | CTI-1601 FDA Approval Call |
| 2023-05-15 08:00 am | CTI-1601 Phase 2 Program Update Call |
| 2023-05-14 | Q1 2023 Earnings Release |
| 2023-05-08 | Annual General Meeting |
| 2023-04-04 04:35 pm | Guggenheim Genomic Medicines and Rare Disease Day |
| 2023-03-14 07:00 am | Q4 2022 Earnings Release |
| 2022-12-01 10:10 am | Piper Sandler Healthcare Conference |
| 2022-11-15 09:00 am | Guggenheim Immunology and Neurology Conference |
| 2022-11-10 07:00 am | Q3 2022 Earnings Release |
| 2022-11-03 05:00 pm | Ataxia Research International Congress |
| 2022-11-02 01:00 pm | Ataxia Research International Congress - Identification of Differentially |
| 2022-11-02 01:00 pm | Ataxia Research International Congress - Tissue Frataxin Increases |
| 2022-09-14 08:30 am | Business Update Call |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | -36,2 -34,8 -3.93% | -41,4 -38,6 -7.31% | -64,2 |
|
EBIT Million USD | Released Forecast Spread | -42,8 -38,2 -12.04% | -50,5 -52,4 3.73% | -36,5 -35,9 -1.74% | -41,8 -38,7 -7.81% | -82,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -42,5 -38,1 -11.61% | -50,6 -59,0 14.23% | -35,4 -35,9 1.53% | -36,9 -34,3 -7.79% | -80,8 |
|
Net income Million USD | Released Forecast Spread | -42,5 -38,1 -11.61% | -50,6 -52,2 3.03% | -35,4 -35,9 1.53% | -36,9 -34,2 -7.89% | -79,9 |
|
EPS USD | Released Forecast Spread | -3,57 -2,76 -29.35% | -2,95 -3,03 2.53% | -1,37 -1,80 23.99% | -0,84 -0,80 -5.33% | -1,23 |
| Announcement Date | 04/03/21 | 25/03/22 | 14/03/23 | 14/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -14,1 -11,3 -25.09% | -12,5 | -14,2 | -17,0 | ||||||||||
|
EBIT Million USD | Released Forecast Spread | -9,09 -14,2 36.14% | -8,89 -9,35 4.97% | -8,69 -9,01 3.6% | -8,51 -8,80 3.26% | -10,4 -10,0 -3.88% | -7,64 -11,3 32.63% | -9,62 -8,27 -16.35% | -10,3 -10,8 4.03% | -14,2 -11,1 -27.19% | -15,3 | -18,5 | -23,3 | -26,2 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -9,13 -17,5 47.9% | -8,94 -9,40 4.86% | -8,67 -9,04 4.12% | -8,32 -8,80 5.45% | -9,43 -9,98 5.6% | -6,53 -11,0 40.66% | -8,37 -7,90 -5.93% | -9,06 -10,0 9.56% | -13,0 -10,3 -26.04% | -14,7 | -17,9 | -22,7 | -25,6 | |
|
Net income Million USD | Released Forecast Spread | -9,13 -14,0 34.83% | -8,94 -9,40 4.86% | -8,67 -9,04 4.12% | -8,32 -8,80 5.45% | -9,43 -9,98 5.6% | -6,53 -11,0 40.66% | -8,37 -7,90 -5.93% | -9,06 -10,0 9.56% | -13,0 -10,3 -26.04% | -15,2 | -18,2 | -22,5 | -25,6 | -30,0 |
|
EPS USD | Released Forecast Spread | -0,50 -0,72 30.23% | -0,49 -0,51 3.92% | -0,47 -0,57 18.02% | -0,37 -0,49 25% | -0,21 -0,42 49.4% | -0,15 -0,25 40.59% | -0,19 -0,20 5% | -0,21 -0,23 8.7% | -0,29 -0,25 -18.37% | -0,24 | -0,28 | -0,34 | -0,38 | -0,45 |
| Announcement Date | 25/03/22 | 12/05/22 | 11/08/22 | 10/11/22 | 14/03/23 | 15/05/23 | 10/08/23 | 14/11/23 | 14/03/24 | - | - | - | - | - |
More events
Past sector events for Larimar Therapeutics, Inc.
| 2024-04-17 | BEIJING KAWIN TECHNOLOGY SHARE-HOLDING CO., LTD.: Q1 2024 Earnings Release (Projected) |
| 2024-04-17 | JIANGSU YAHONG MEDITECH CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LRMR Stock
- Calendar Larimar Therapeutics, Inc.
